ClinicalTrials.govpublic full text
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
beta-thalassemia major, sickle cell disease, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 845044
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.